Aims: GIOIA is an ongoing prospective multicentre study aiming to assess the vascular and metabolic effects of SGLT-2 inhibitors (gliflozins) and DPP-4 inhibitors (gliptins) in the routine clinical practice of patients with type 2 diabetes (T2D). Herein we describe the preliminary effectiveness data at 6 months. Methods: SGLT-2i and DPP-4i-naïve adult patients with T2D (N = 301 and 260, respectively), with glycated haemoglobin A1c (A1C) >7%, an estimated glomerular filtration rate (eGFR) ≥60 ml/min/1.73 m2, on background therapy with metformin, insulin or both, are being followed to evaluate markers of vascular (carotid intima-media thickness), myocardial (myocardial diastolic function) and renal (urinary albumin/creatinine ratio) damage...
Aims: According to cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (S...
BackgroundThe last international consensus on the management of type 2 diabetes (T2D) recommends SGL...
peer reviewedSodium-glucose cotransporter type 2 (SGLT2) inhibitors (SGLT2i; gliflozins) exert their...
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glu...
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glu...
peer reviewedSodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1 re...
In randomized controlled trials (RCTs), SGLT-2 inhibitors (SGLT2i) showed glycaemic and extra-glycae...
Aims: According to cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (S...
International audienceBACKGROUND: The last international consensus on the management of type 2 diabe...
Sodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication a...
Aims: According to cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (S...
BackgroundThe last international consensus on the management of type 2 diabetes (T2D) recommends SGL...
peer reviewedSodium-glucose cotransporter type 2 (SGLT2) inhibitors (SGLT2i; gliflozins) exert their...
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glu...
Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glu...
peer reviewedSodium-glucose cotransporter type 2 inhibitors (SGLT2is) and glucagon-like peptide-1 re...
In randomized controlled trials (RCTs), SGLT-2 inhibitors (SGLT2i) showed glycaemic and extra-glycae...
Aims: According to cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (S...
International audienceBACKGROUND: The last international consensus on the management of type 2 diabe...
Sodium-glucose co-transporter-2 (SGLT2) inhibitors (gliflozins) are the newest class of medication a...
Aims: According to cardiovascular outcome trials, some sodium-glucose contransporter-2 inhibitors (S...
BackgroundThe last international consensus on the management of type 2 diabetes (T2D) recommends SGL...
peer reviewedSodium-glucose cotransporter type 2 (SGLT2) inhibitors (SGLT2i; gliflozins) exert their...